Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA against LRP8
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
siRNA against LRP8 is a small interfering RNA (siRNA) designed to silence the expression of low-density lipoprotein receptor-related protein 8 (LRP8, also known as apolipoprotein E receptor 2 or apoER2). LRP8 is a cell-surface receptor that is frequently overexpressed or amplified in triple-negative breast cancer (TNBC) and other estrogen receptor-negative breast cancers. Silencing LRP8 with siRNA inhibits the ApoE-LRP8/VLDLR signaling axis, leading to decreased cell proliferation, increased apoptosis, and suppression of breast cancer stem cells (BCSCs) and tumorigenesis, particularly under nutrient-depleted conditions. It has been studied primarily in preclinical research as a potential therapeutic target for TNBC.
- Other names
- LRP8 siRNALRP-8 siRNALRP 8 siRNAsiLRP8siLRP-8siLRP 8
02
Targets
LRP8 (Apolipoprotein E receptor 2)
Beyond the preview
Go deeper on siRNA against LRP8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA against LRP8.